Two months after former Seagen CEO David Epstein unveiled his new project, the biotech has secured "over" $140 million in ...
Another checkpoint inhibitor has entered the fray, as Checkpoint Therapeutics has passed the FDA’s checkpoint with its PD-L1 inhibitor cosibelimab. The FDA has approved cosibelimab under the brand ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback